Hepatitis D (HDV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

The overall prevalence of HBV/HDV co-infection was determined to be 8%, with cirrhosis present in 73% of the co-infected, 80% of the tri-infected (HDV/HBV along with hepatitis C infection), but only 22% of HBV mono-infection.

Read more:- Hepatitis D (HDV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Chronic-hepatitis-delta-virus-HDV-infection-forecast

Comprehensive insight on patient segmentation based on Age group, Sex, Isolates (Genotype – I, II & III), co-infection with HDV and HBV of a susceptible, anti-HBs-negative individual, and HDV superinfection of a chronic HBV carrier, Type of settings (Acute & Chronic) has been provided into the epidemiology (Incidence and Prevalence) section of the HDV and its treatment in the 8 MM coun-tries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

CI IMAGE

Despite interferon-a (IFNa) & Peg-iFn-? usage, the primary concern is the prevention of the progression of the disease and its lateral damages such as cirrhosis, liver failure, and carcinoma. Currently companies like Roche; Pegasys, Replicor Inc.; REP 2139-Ca + Pegasys, MYR Pharma; Myrcludex B, Eiger BioPharmaceuti-cals; Lonafarnib, Eiger BioPharmaceuticals; Pegylated interferon lambda 1a. The market is expected to witness rapid growth with the launch of designated emerging therapies, such as Myrcludex B; MYR Pharma (Orphan designation), Lonafarnib; Eiger BioPharmaceuti-cals (Fast Track & Orphan designation). Myrcludex B showed a strong effect on HDV RNA serum levels and induced ALT normalization under monotherapy. Among the key assets, some of the companies like Merck Sharp & Dohme Corp., Gilead Sciences, Arrowhead Pharmaceuticals, and Boehringer Ingelheim are in the race to build their assets within the market space

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Other Reports:-
Chemoradiation-induced oral mucositis (CRIOM) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Obstructive Sleep Apnea (OSA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Social Anxiety Disorder (SAD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Hereditary ATTR Amyloidosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Knee osteoarthritis (OA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Hepatitis D (HDV) competitive landscape, Hepatitis D (HDV), Hepatitis D (HDV) market outlook report, Hepatitis D (HDV) market forecast